In the same study, Gal-3 silencing in A549 lung cancer epithelial cells reduced the TGFR-β levels at the cell surface and the TGF-β1-mediated activation of β-catenin is restored by Gal-3 treatment (Fig. 4e) [122]. The gene discussed is LGALS3; the disease is lung cancer.